Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811131 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT04811131 is a Phase 2 study that was terminated before completion, run by Arcutis Biotherapeutics. The registered enrollment target is 114 participants.
The verdict
NCT04811131, a Phase 2 study, was terminated before completion, sponsored by Arcutis Biotherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
Interventions
- DRUG ARQ-252 cream 0.3%
- DRUG ARQ-252 Vehicle cream
- DEVICE NB-UVB phototherapy active treatment
- DEVICE NB-UVB phototherapy sham treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2021-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04811131
The ClinicalTrials.gov registry entry for NCT04811131 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ARQ-252 cream 0.3% is the first listed.
NCT04811131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04811131 about?
NCT04811131 is a clinical study titled "Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo". This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
What is the current status of trial NCT04811131?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2021-03-04. Estimated completion is 2021-08-09.
What interventions are being tested in trial NCT04811131?
The interventions under investigation include: ARQ-252 cream 0.3% (DRUG), ARQ-252 Vehicle cream (DRUG), NB-UVB phototherapy active treatment (DEVICE), NB-UVB phototherapy sham treatment (DEVICE).
Who is sponsoring clinical trial NCT04811131?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.